Long-Term Treatment With EPO Increases Serum Levels of High-Density Lipoprotein in Patients With CKD

American Journal of Kidney Diseases

Volumn 48, Issue 2, 2006, Pages 242-249

  Siamopoulos, Kostas C ^a,b   Gouva, Chariklia ^a,b   Katopodis, Konstantinos P ^a,b   Tzallas, Christos ^a,b   Nikolopoulos, Peter ^a,b   Papavasiliou, Eleni C ^a,b   Tselepis, Alexandros D ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

chronic kidney disease (CKD); erythropoietin (EPO); lipids; Renal anemia

Indexed keywords

HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33745917379     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.04.071     Document Type: Article

References (41)

1. Samuelsson O., Mulec H., Knight-Gibson C., et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12 (1997) 1908-1915
2. Eschbach J.W., Egrie J.C., Downing M.R., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316 (1987) 73-78
3. Kokot F., Wiecek A., Grzeszczak W., Klepacka J., Klin M., and Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. Contrib Nephrol 76 (1989) 257-272
4. Fischer C., Scigalla P., Park W., et al. Influence of rhuEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contrib Nephrol 76 (1989) 250-256
5. Riedel E., Hampl H., Scigalla P., Nundel M., and Kessel M. Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients. Kidney Int 27 Suppl (1989) S216-S221
6. Kokot F., Wiecek A., Marcinkowski W., Rudka R., and Trembecki J. Suppression of the pituitary-adrenal axis and somatotropin (HGH) secretion is time-dependent in haemodialyzed patients (HDP) with chronic uraemia on long-term erythropoietin (Epo) therapy. Nephrol Dial Transplant 7 (1992) 445-449
7. Grimm P.C., Sinai-Triema L., Sekiya N.M., et al. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38 (1990) 12-18
8. Temple R.M., Langan S.J., Deary I.J., and Winney R.J. Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients. Nephrol Dial Transplant 7 (1992) 240-245
9. Nissenson A.R. Recombinant human erythropoietin. Impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 9 suppl 2 (1989) S25-S31
10. Braumann K.M., Nonnast-Daniel B., Boning D., Bocker A., and Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 58 (1991) 129-134
11. Lundin A.P., Akerman M.J.H., Chesler R.M., et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 58 (1991) 315-319
12. Gouva C., Nikolopoulos P., Ioannidis J.P.A., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function. A randomized controlled trial. Kidney Int 66 (2004) 753-760
13. Papavasiliou E.C., Gouva C., Siamopoulos K.C., and Tselepis A.D. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease. Effect of long term therapy with erythropoietin. Kidney Int 68 (2005) 246-255
14. Prata M.-M., Madeira C., Vicente O., and Miguel M.J.P. Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 13 (1998) 2345-2347
15. Pollock C.A., Wyndham R., Collet P.V., et al. Effects of erythropoietin on the lipid profile in end-stage renal failure. Kidney Int 45 (1994) 897-902
16. Allegra V., Martimbianco L., and Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy. Roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant 12 (1997) 924-932
17. Goto T., Saika H., Takahashi T., Maeda A., Mune M., and Yukawa S. Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients. Kidney Int Suppl 71 (1999) S213-S215
18. Teplan V., Schuck O., Knotek A., Hajney J., Horackova M., and Kvapil M. Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet. Czech Multicenter Study. Am J Kidney Dis 41 suppl 1 (2003) S26-S30
19. Assman G., and Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 (2004) 8-14
20. Forrester S.J., Makkar R., and Shah P.K. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition. An update for clinicians. Circulation 111 (2005) 1847-1854
21. Ordovas J.M., Cupples L.A., Corella D., et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham Study. Arterioscler Thromb Vasc Biol 20 (2000) 1323-1329
22. Milionis H.J., Elisaf M.S., Karabina S.-A.P., Bairaktari E., Tselepis A.D., and Siamopoulos K.C. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int 56 (1999) 2276-2285
23. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 24 (1997) 2413-2446
24. Matsumura M., Nomura H., Koni I., and Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Nephron 77 (1997) 164-168
25. Albitar S., Genin R., Fen-Chong M., et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13 (1998) 1206-1210
26. MacDougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14 (1999) 1836-1841
27. Maroni B.J. Protein restriction in the pre-end-stage renal disease (ESRD) patient. Who, when, how, and the effect on subsequent ESRD outcome. J Am Soc Nephrol 9 suppl 12 (1998) S100-S106
28. Tsimihodimos V., Karabina S.-A.P., Tambaki A., et al. Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 43 (2002) 256-263
29. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
30. Yamashita S., Sakai N., Hirano K., et al. Molecular genetics of plasma cholesteryl ester transfer protein. Curr Opin Lipidol 8 (1997) 101-110
31. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res 34 (1993) 1255-1274
32. Gotto Jr. A.M. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease. A working group report. Circulation 103 (2001) 2213-2218
33. de Grooth J.G., Smilde J.T., van Wissen S., et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 173 (2004) 261-267
34. Fruchart J.C. Peroxisome proliferator-activated receptor-activation and high-density lipoprotein metabolism. Am J Cardiol 88 (2001) 24N-29N
35. Stenvinkel P. Anemia and inflammation. What are the implications for the nephrologists?. Nephrol Dial Transplant 18 suppl 8 (2003) Sviii17-Sviii22
36. Baranova I., Vishnyakova T., Bocharov A., et al. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun 70 (2002) 2995-3003
37. Esteve E., Ricart W., and Fernandez-Real J.M. Dyslipidemia and inflammation. An evolutionary conserved mechanism. Clin Nutr 24 (2005) 16-31
38. Aguilera A., and Selgas R. Effect of recombinant human erythropoietin on inflammatory status in dialysis patients. Nephrol Dial Transplant 19 suppl 5 (2004) Sv46-Sv53
39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
40. 2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 3 (2002) S57-S68
41. Papavasiliou E.C., Gouva C., Siamopoulos K.C., and Tselepis A.D. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant 21 (2006) 1270-1277